Interferón alfa 2b para el ojo refractario de la enfermedad de Behçet.

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study.

BMC immunology·2025

Improving organisation to improve care: ERN ReCONNET organisational reference model for systemic sclerosis patients' care pathway.

Journal of scleroderma and related disorders·2024

Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.

Clinical immunology (Orlando, Fla.)·2024

Assessment of conjunctival, episcleral and scleral thickness in healthy individuals using anterior segment optical coherence tomography.

Acta ophthalmologica·2023

Long-term data on efficacy and safety of adalimumab in Behçet's disease.

Clinical immunology (Orlando, Fla.)·2023

Adult orbital xanthogranuloma: long-term follow-up of treated cases.

Eye (London, England)·2022

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

Case reports in dermatological medicine·2026

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

Frontiers in endocrinology·2026

Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.

Kidney diseases (Basel, Switzerland)·2026

Diffuse Large B-cell Lymphoma Initially Managed As Secondary Immune Thrombocytopenia: A Case Report.

Cureus·2026

Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus.

Frontiers in lupus·2026

Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.

Frontiers in cell and developmental biology·2026

Videos de Experimentos Relacionados

Interferón alfa 2b para el ojo refractario de la enfermedad de Behçet.

Videos de Conceptos Relacionados

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study.

Improving organisation to improve care: ERN ReCONNET organisational reference model for systemic sclerosis patients' care pathway.

Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.

Assessment of conjunctival, episcleral and scleral thickness in healthy individuals using anterior segment optical coherence tomography.

Long-term data on efficacy and safety of adalimumab in Behçet's disease.

Adult orbital xanthogranuloma: long-term follow-up of treated cases.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.

Diffuse Large B-cell Lymphoma Initially Managed As Secondary Immune Thrombocytopenia: A Case Report.

Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus.

Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.

Videos de Experimentos Relacionados

Interferón alfa 2b para el ojo refractario de la enfermedad de Behçet.

Videos de Conceptos Relacionados

Artículos Relacionados